头颈部肿瘤多瘤抑制基因p16表达研究  

The exprimental research on the expression of tumor suppressor gene p16 in the head and neck neoplasms

作　　者：傅新文[1] 胡银英[2] 宋晓萍[1] 袁铿[2] 郭江梅[1] 袁佳蕾[3] 李龚琼[4] 刘利[1] 张民宪[5] 

机构地区：[1]江西省人民医院,江西南昌330006 [2]江西省医学科学研究所 [3]赣南医学院临床医学系 [4]江西省妇幼保健院 [5]南昌大学现代教育技术中心

出　　处：《实验与检验医学》2010年第5期439-440,452,共3页Experimental and Laboratory Medicine

基　　金：江西省自然科学基金(0440138)

摘　　要：目的探讨多瘤抑癌基因蛋白p16表达与原发性和继发性头颈部肿瘤生物学行为之间的关系。方法通过细针吸取及术中印片细胞学诊断病例获取标本,进行免疫细胞化学技术分析,检测220例头颈部良、恶性肿瘤及其他病变中p16蛋白表达水平,并对头颈部肿瘤组织学类型、分化程度的关系进行分析研究。结果 p16蛋白在头颈部良性病变的阳性表达率为84.63%,明显高于恶性肿瘤的表达率53.90%,差异有显著性(P<0.05)。p16蛋白表达与恶性肿瘤的细胞分化程度有关,高分化肿瘤其表达水平明显高于低分化肿瘤,同时显示p16蛋白表达程度与头颈部肿瘤大小及有无转移均无明显关联。结论多瘤抑癌基因蛋白p16参与了肿瘤的发生及分化,检测p16蛋白表达水平,可能成为肿瘤诊断和预测预后的一项新指标。Objective To explore the relationship between the expression of multiple tumor suppressor gene p16 of oncocytes and the biological behaviour of the head and neck neoplasms.Methods Two hundred and twenty cytological specimens from the head and neck lesions for p16 protein expression were detected by the methods of fine needle aspiration cytology and intraoperative imprint cytology combining with immunocytochemical staining technique.The relationship between p16 protein expression and the pathological type,differention grading of the head and neck tumors was analysed.Results p16 protein positive expression of the benign lesions was 84.63%,and with 53.90% of the malignant tumors in the head and neck.The results showed a significant statistical difference（P〈0.05）.P16 protein expression was correlated with the cellular differentiation of malignant tumors,and its expression level in well differentiated tumors was significantly higher than that of poorly differentiated tumors,also showed the level of p16 protein expression was no significant correlation in tumor size and metastasis of the head and neck.Conclusions Multiple tumor suppressor gene p16 is involved in tumorigenesis and differentiation,p16 protein expression detection may be a new index for the tumor diagnosis and prognosis.

关 键 词：多瘤抑制基因p16 基因表达 头颈部肿瘤/细胞学 

分 类 号：Q786[生物学—分子生物学] R730.43[医药卫生—肿瘤]